Jan 20 (Reuters) - Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have ...

Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.

Vancouver company’s 3-D live tissue-printing technology will incorporate key biological materials and receive new investment from Danish pharma giant ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Novo and Aspect have been collaborating since 2023 to develop cellular medicines. ・Under the deal, Aspect has acquired rights ...

Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will ...

Novo Nordisk NVO and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". New 3D therapeutic models of the blood-brain barrier could lead to ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems (“Aspect”) (“the Company”), a biotechnology company pioneering microfluidic 3D bioprinting of human tissues, today announced a US $20 ...

Danish pharma major Novo Nordisk and privately-held Vancouver-based Aspect Biosystems today announced they are entering a new ...

Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will ...